IONETIX is a pioneering radiopharmaceutical end-to-end solution provider.
Founded in 2009 from technology born at MIT Plasma Science and Fusion Center, IONETIX developed the world’s first commercial compact superconducting cyclotron, the ION-12SC.
Used to produce N-13 Ammonia, one of the most accurate PET imaging agents for the detection of CAD1, IONETIX is actively establishing a network of ION-12SCs installed on or near the campus of PET programs across the country. By covering all costs related to the installation and ongoing operation of the cyclotron and making N-13 Ammonia available to providers through a pay-by-the-dose model, IONETIX is making this critical tracer accessible and affordable to providers nationwide.
More recently, IONETIX is leveraging its growing network of radiopharmaceutical manufacturing locations to support the development and commercialization of targeted alpha therapy (TAT). An emerging cancer therapy utilizing alpha radionuclides, TAT delivers high-energy alpha particles to cancer cells and the tumor microenvironment to treat cancer while preserving healthy tissue.
1https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382649
Management Team
-
KEVIN J CAMERON
CHIEF EXECUTIVE OFFICER
Prior to joining Ionetix in 2011, Mr. Cameron served as President of Glass, Lewis & Co., a leading independent corporate governance research firm which he co-founded in 2003. Prior to Glass Lewis, he served as General Counsel at Moxi Digital, a technology venture founded by Microsoft co-founder Paul Allen. Mr. Cameron previously served as General Counsel at NorthPoint Communications, a publicly-traded broadband telecommunications company acquired by AT&T. Before NorthPoint, he was an attorney with the corporate law firm of Kellogg, Huber, Hansen, Todd & Evans in Washington D.C. and served as a law clerk to the Hon. James L. Buckley of the United States Court of Appeals for the District of Columbia Circuit. Mr. Cameron is a director of KERYX Biopharmaceuticals (NASD:KERX), a director of AvidBiotics, a former director of Reddy Ice, and was a founding board member of ProCure Treatment Centers, the leading provider of proton therapy treatment in the U.S. He earned a J.D. from the University of Chicago and a B.A. at McGill University.
-
ANTHONY STAGNOLIA
CHIEF OPERATIONS OFFICER
Prior to joining Ionetix in 2017, Mr. Stagnolia served as COO for Zevacor Pharma (formerly IBA Molecular NA), a leader in radiopharmaceutical manufacturing and distribution. Prior to joining IBA Molecular NA, he served as COO for PETNET Solutions, A Siemens Company. PETNET Solutions operates the largest network of PET radiopharmacies with a global network of integrated manufacturing operations and PET nuclear pharmacies. Prior to joining PETNET Solutions, Mr. Stagnolia held multiple manufacturing and operational leadership positions at International Paper Company. He earned his B.S. in Chemical Engineering from the University of Tennessee and M.B.A from the University of Memphis.
-
JOHN VINCENT
VP, ENGINEERING & NEW PRODUCT DEVELOPMENT
Prior to joining Ionetix in 2012, Dr. Vincent served as the Chief Engineer and Electronics Department Head at the National Superconducting Cyclotron Laboratory at Michigan State University. He previously held the position of RF Project Leader at NSCL. Dr. Vincent is a veteran of the United States Army. He earned his Ph.D., M.S. and B.S. in Electrical Engineering from Michigan State University.
-
DAVID EVE
VP, MEDICAL AFFAIRS
Prior to joining Ionetix in 2013, Mr. Eve served as Vice President of Operations and Strategic Development at Soteria Imaging Services, LLC, a national leader in outpatient medical imaging. He previously served as Vice President of Technical Services, Vice President of PET Operations and Director of Facility Operations. Mr. Eve earned his B.S. in Nuclear Medicine from Wheeling Jesuit University.
-
PETER BURKE
VP, SALES & MARKETING
Prior to joining Ionetix in 2020, Mr. Burke served as Vice President of Sales Marketing for SOFIE (formerly IBA Molecular NA), a leader in commercial radiopharmaceutical manufacturing and research. From 2000 to 2012 Mr. Burke was a leader at Cardinal Health Nuclear Pharmacy services, (formerly Syncor), holding numerous Sales, Marketing and Operational roles. Peter is a graduate of the Ohio State University.
